Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/4/2024 | $5.00 | Neutral | Mizuho |
8/9/2024 | $10.00 | Outperform → Strong Buy | Raymond James |
5/23/2024 | $8.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
5/16/2024 | $10.00 | Mkt Perform → Outperform | Raymond James |
4/10/2024 | $9.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
3/25/2024 | $7.50 → $10.00 | Equal Weight → Overweight | Wells Fargo |
3/1/2024 | $7.00 → $10.00 | Neutral → Overweight | JP Morgan |
2/26/2024 | $8.00 | Outperform | Leerink Partners |
SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
144 - GoodRx Holdings, Inc. (0001809519) (Subject)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00
Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00
RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously
Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for
Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy
Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca